Clinical Trial

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Study acronym: TMF-Allo
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Trial Details
NCT Number NCT04935684
Lead Sponsor University Hospital, Clermont-Ferrand
Collaborators: Ministry of Health, France, French Society of Hematology
Conditions Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Chronic Lymphocytic Leukemia
Enrollment 150 participants
Start Date 2022-12-20
Primary Completion 2030-05 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-09